Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer

Epidemiology of Traumatic Brain Injury in Europe: A Living Systematic Review

(2016) Alexandra Brazinova et al.   JOURNAL OF NEUROTRAUMA

A New Approach to Evidence Synthesis in Traumatic Brain Injury: A Living Systematic Review

(2016) Anneliese Synnot et al.   JOURNAL OF NEUROTRAUMA

Adherence to Guidelines in Adult Patients with Traumatic Brain Injury: A Living Systematic Review

(2016) Maryse C. Cnossen et al.   JOURNAL OF NEUROTRAUMA

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations

(2015) Brian Hutton et al.   ANNALS OF INTERNAL MEDICINE

How Good Is “Evidence” from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?

(2015) Huseyin Naci et al.   Annual Review of Pharmacology and Toxicology

Meta-analysis of Seven Randomized Control Trials to Assess the Efficacy and Toxicity of Combining EGFR-TKI with Chemotherapy for Patients with Advanced NSCLC who Failed First-Line Treatment

(2015) Bing-Kun Xiao et al.   Asian Pacific Journal of Cancer Prevention

Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination

(2015) Bartosz Helfer et al.   BMC Medicine

Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non–Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials

(2015) Claire L. Vale et al.   Clinical Lung Cancer

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis

(2015) Sanjay Popat et al.   Future Oncology

Automating Risk of Bias Assessment for Clinical Trials

(2015) Iain J Marshall et al.   IEEE Journal of Biomedical and Health Informatics

A Living Systematic Review of Nebulized Hypertonic Saline for Acute Bronchiolitis in Infants

(2015) Robert G. Badgett et al.   JAMA Pediatrics

The Global Burden of Cancer 2013

(2015) Christina Fitzmaurice et al.   JAMA Oncology

A Living Meta-analysis of Colchicine for Pericarditis

(2014) Patrick Ters et al.   ANNALS OF PHARMACOTHERAPY

Using conditional power of network meta-analysis (NMA) to inform the design of future clinical trials

(2014) Adriani Nikolakopoulou et al.   BIOMETRICAL JOURNAL

Meta-Analysis to Assess the Efficacy and Toxicity of Docetaxel-Based Doublet Compared with Docetaxel Alone for Patients with Advanced NSCLC who Failed First-Line Treatment

(2014) Ying Jin et al.   CLINICAL THERAPEUTICS

Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials

(2014) Xuyuan Li et al.   CURRENT MEDICAL RESEARCH AND OPINION

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

(2014) June-Koo Lee et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Reducing systematic review workload through certainty-based screening

(2014) Makoto Miwa et al.   JOURNAL OF BIOMEDICAL INFORMATICS

How to increase value and reduce waste when research priorities are set

(2014) Iain Chalmers et al.   LANCET

Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: A meta-analysis of randomized controlled clinical trials

(2014) Ning Zhao et al.   LUNG CANCER

A Bayesian Mixed-Treatment Comparison Meta-analysis of Treatments for Alcohol Dependence and Implications for Planning Future Trials

(2014) Stacia M. DeSantis et al.   MEDICAL DECISION MAKING

Using Crowdsourcing to Evaluate Published Scientific Literature: Methods and Example

(2014) Andrew W. Brown et al.   PLoS One

Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer

(2014) Ning Li et al.   PLoS One

Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses

(2014) Wenhua Liang et al.   PLoS One

The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review

(2014) XiongWen Yang et al.   Current Oncology Reports

Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer

(2014) Maria Antonia Pérez-Moreno et al.   International Journal of Clinical Pharmacy

A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis

(2014) M. A. Puhan et al.   BMJ-British Medical Journal

Impact of sending email reminders of the legal requirement for posting results on ClinicalTrials.gov: cohort embedded pragmatic randomized controlled trial

(2014) A. Maruani et al.   BMJ-British Medical Journal

Living Systematic Reviews: An Emerging Opportunity to Narrow the Evidence-Practice Gap

(2014) Julian H. Elliott et al.   PLOS MEDICINE

Exploring the Geometry of Treatment Networks

(2013) Georgia Salanti et al.   ANNALS OF INTERNAL MEDICINE

Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis

(2013) Wei-Xiang Qi et al.   Asian Pacific Journal of Cancer Prevention

From ClinicalTrials.gov trial registry to an analysis-ready database of clinical trial results

(2013) M Soledad Cepeda et al.   Clinical Trials

Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses

(2013) Huseyin Naci et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents

(2013) Anna-Bettina Haidich et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Evidence Synthesis for Decision Making 1

(2013) Sofia Dias et al.   MEDICAL DECISION MAKING

Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data

(2013) Wei-Xiang Qi et al.   PLoS One

The Geometric Increase in Meta-Analyses from China in the Genomic Era

(2013) John P. A. Ioannidis et al.   PLoS One

The Efficacy of Bevacizumab Compared with Other Targeted Drugs for Patients with Advanced NSCLC: A Meta-Analysis from 30 Randomized Controlled Clinical Trials

(2013) Jianlan Cui et al.   PLoS One

The automation of systematic reviews

(2013) G. Tsafnat et al.   BMJ-British Medical Journal

Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review

(2013) A. Bafeta et al.   BMJ-British Medical Journal

Overlapping meta-analyses on the same topic: survey of published studies

(2013) K. C. Siontis et al.   BMJ-British Medical Journal

The effects of excluding treatments from network meta-analyses: survey

(2013) E. J. Mills et al.   BMJ-British Medical Journal

Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis

(2012) Wei-Xiang Qi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty

(2012) Asba Tasneem et al.   PLoS One

Tocolytic therapy for preterm delivery: systematic review and network meta-analysis

(2012) D. M. Haas et al.   BMJ-British Medical Journal

Noninferiority Trials in Second-Line Treatments of Nonsmall Cell Lung Cancer

(2011) Davide Tassinari et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer

(2011) Wei-Xiang Qi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Need to realign patient-oriented and commercial and academic research

(2011) Alessandro Liberati   LANCET

The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials

(2011) Wei-Xiang Qi et al.   LUNG

Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials

(2010) Jingwei Jiang et al.   ACTA ONCOLOGICA

Semi-automated screening of biomedical citations for systematic reviews

(2010) Byron C Wallace et al.   BMC BIOINFORMATICS

Seventy-Five Trials and Eleven Systematic Reviews a Day: How Will We Ever Keep Up?

(2010) Hilda Bastian et al.   PLOS MEDICINE

Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses

(2009) J. P.A. Ioannidis   CANADIAN MEDICAL ASSOCIATION JOURNAL

Second-Line Treatments in Non-small Cell Lung Cancer

(2009) Davide Tassinari et al.   CHEST

AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews

(2009) Beverley J. Shea et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

No Study Left Behind: A Network Meta-Analysis in Non–Small-Cell Lung Cancer Demonstrating the Importance of Considering All Relevant Data

(2009) Neil Hawkins et al.   VALUE IN HEALTH